… pharmaceutical ingredients. Every member of our more than 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time. Learn more at mylan.com largest and fully-integrated, innovation-led biopharmaceutical …
Category: Herceptin, Trastuzumab (generic)
Biosimilars in Europe: 2016 Year in Review and What’s Ahead
Europe’s biosimilar market continues to develop, with biosimilars in new classes approved and pending in applications before the European Medicines Agency . 22 biosimilars are approved in eight different product classes and 16 biosimilar applications, including applications in four new product classes, are pending as of December 1, 2016.
Oncology Drug Report – Kadcyla – ado-trastuzumab emtansine -…
Kadcyla : Armed antibody is a comprehensive report on the first USFDA approved drug with antibody-drug conjugate for HER2-positive metastatic breast cancer treatment. Kadcyla falls in the monoclonal antibody, HER 2-targeted antibody-drug conjugate, class of drugs belonging to the targeted therapy.